Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 3/20 | 0.58 |
| ▸ | EGLN2 | Q96KS0 | 2/20 | 0.34 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.32 |
| ▸ | TTR | P02766 | 1/20 | 0.31 |
| ▸ | ALB | P02768 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1806589 | 0.84 | TRPV4 (0.43) | TRPV4 | |
| SCHEMBL24253799 | 0.79 | TRPV4 (0.52) | TRPV4EGLN2TTRALB | |
| SCHEMBL185766 | 0.78 | TRPV4 (0.64) | TRPV4EGLN2 | |
| SCHEMBL6649045 | 0.76 | TRPV4 (0.61) | TRPV4EGLN2TTRALB | |
| SCHEMBL24070359 | 0.75 | TRPV4 (0.59) | TRPV4EGLN2 | |
| SCHEMBL13816946 | 0.74 | TRPV4 (1.00) | TRPV4EGLN2 | |
| SCHEMBL14677092 | 0.74 | TRPV4 (0.58) | TRPV4EGLN2MAP2K1 | |
| SCHEMBL19356876 | 0.74 | TRPV4 (0.58) | TRPV4EGLN2 | |
| SCHEMBL1947934 | 0.74 | TRPV4 (0.58) | TRPV4EGLN2 | |
| SCHEMBL81244 | 0.74 | TRPV4 (0.58) | TRPV4EGLN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024086246-A2 | 2-SUBSTITUTED 3,4 A, 5, 7, 8, 8 A-HEXAHYDRO-4H-THIOP YRANO [4,3- DJPYRIMIDIN-4-ONES FOR WOUND TREATMENT | Eluciderm Inc. (US) | 2024-04-25 | — | — | WO | disclosed |
| WO-2024086246-A2 | 2-SUBSTITUTED 3,4 A, 5, 7, 8, 8 A-HEXAHYDRO-4H-THIOP YRANO [4,3- DJPYRIMIDIN-4-ONES FOR WOUND TREATMENT | Eluciderm Inc. (US) | 2024-04-25 | — | — | WO | disclosed |
| US-8263615-B2 | Bis-heterocyclic imidazolyl compounds | NOVARTIS AG (CH) | 2012-09-11 | — | — | US | disclosed |
| US-8138176-B2 | Imidazo compounds | NOVARTIS AG (CH) | 2012-03-20 | — | — | US | disclosed |
| US-8076327-B2 | Condensed imidazole derivatives as aldosterone synthase inhibitors | NOVARTIS AG (CH) | 2011-12-13 | — | — | US | disclosed |
| US-20110092492-A1 | IMIDAZO COMPOUNDS | HEROLD PETER | 2011-04-21 | — | — | US | disclosed |
| US-7879847-B2 | such as 4-(5,6-Dihydro-8H-imidazo[5,1-c][1,4]oxazin-5-yl)benzonitrile, having aldosterone synthase and/or 11- beta -hydroxylase inhibitory activity, used for the treatment of hypertension and Cushing's Syndrome | NOVARTIS AG (CH) | 2011-02-01 | — | — | US | disclosed |
| US-20100305110-A1 | CONDENSED IMIDAZOLE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS | NOVARTIS AG (CH) | 2010-12-02 | — | — | US | disclosed |
| EP-2004658-B1 | CONDENSED IMIDAZOLE DERIVATIVES AS AROMATASE INHIBITORS | NOVARTIS AG (CH) | 2010-10-13 | — | — | EP | disclosed |
| US-7799780-B2 | Condensed imidazole derivatives as aldosterone synthase inhibitors | NOVARTIS AG (CH) | 2010-09-21 | — | — | US | disclosed |
| EP-2004658-A1 | CONDENSED IMIDAZOLE DERIVATIVES AS AROMATASE INHIBITORS | Speedel Experimenta AG (CH) | 2008-12-24 | — | — | EP | disclosed |
| EP-1957489-A2 | BIS-HETEROCYCLIC IMIDAZOLYL COMPOUNDS | Speedel Experimenta AG (CH) | 2008-08-20 | — | — | EP | disclosed |
| WO-2007116097-A1 | CONDENSED IMIDAZOLE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS | SPEEDEL EXPERIMENTA AG (CH) | 2007-10-18 | — | — | WO | disclosed |
| WO-2007116100-A1 | CONDENSED IMIDAZOLE DERIVATIVES AS AROMATASE INHIBITORS | SPEEDEL EXPERIMENTA AG (CH) | 2007-10-18 | — | — | WO | disclosed |
| WO-2007116101-A1 | IMIDAZO COMPOUNDS | SPEEDEL EXPERIMENTA AG (CH) | 2007-10-18 | — | — | WO | disclosed |
| WO-2007116099-A1 | IMIDAZO COMPOUNDS | SPEEDEL EXPERIMENTA AG (CH) | 2007-10-18 | — | — | WO | disclosed |
| WO-2007065942-A2 | BIS-HETEROCYCLIC IMIDAZOLYL COMPOUNDS | SPEEDEL EXPERIMENTA AG (CH) | 2007-06-14 | — | — | WO | disclosed |
| EP-0442266-B1 | Tolan derivatives, liquid crystal compositions containing them, and liquid crystal elements using them | SEIKO EPSON CORP (JP) | 1994-12-28 | — | — | EP | disclosed |
| US-5314640-A | Tolan derivatives, liquid crystal compositions including same, liquid crystal display devices including the compositions and method of preparation | SEIKO EPSON CORPORATION (JP) | 1994-05-24 | — | — | US | disclosed |
| EP-0442266-A1 | Tolan derivatives, liquid crystal compositions containing them, and liquid crystal elements using them | SEIKO EPSON CORPORATION (JP) | 1991-08-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305110-A1 | CONDENSED IMIDAZOLE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS | CYP11B1, CYP11B2, REN | TRPV4 3518/4885EGLN2 1320/4885MAP2K1 1697/4885 |
| US-20110092492-A1 | IMIDAZO COMPOUNDS | REN, CYP11B2, CYP11B1 | TRPV4 3677/4885EGLN2 1669/4885MAP2K1 2987/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.